# Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon

> **NCT06696664** · — · RECRUITING · sponsor: **Minghui Li** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** PEG-IFN-α

## Key facts

- **NCT ID:** NCT06696664
- **Lead sponsor:** Minghui Li
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06696664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06696664, "Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06696664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*